The Sinclair Longevity Protocol: What the Public Record Says
A regimen that shaped a market, read alongside the evidence for each component and the scientific disputes the popular account leaves out.
The Short Answer
David Sinclair's publicly discussed personal regimen did more to create the NAD+ supplement market than any trial. It is worth examining for two reasons: the components have individually assessable evidence, and the theoretical framework behind it, the information theory of ageing, is the subject of genuine scientific disagreement that popular coverage tends to omit. What follows addresses the publicly discussed components and the state of evidence for each. Personal regimens change and are described inconsistently across interviews, so the primary sources govern on specifics.
The Publicly Discussed Components
Across published interviews and his book, the regimen has been described as including a nicotinamide adenine dinucleotide precursor, resveratrol taken with a fat source, metformin, and a set of foundational compounds including vitamin D, vitamin K2 and omega-3, alongside a compressed eating window, regular exercise and periodic cold and heat exposure.
The composition reported has varied over time and between interviews, which is expected of anyone's personal practice and is a reason not to read any published list as authoritative.
Two of the components, metformin and any NAD+ precursor at pharmacological intent, sit at or beyond the boundary of consumer supplementation. Metformin is a prescription medicine in most jurisdictions.
Component by Component
| Component | Human evidence |
|---|---|
| NMN or NR | Raises blood NAD+ reliably. Downstream functional benefits in healthy adults are inconsistent across trials |
| Resveratrol | Poor oral bioavailability, extensive glucuronidation. Human trials largely disappointing; the sirtuin activation mechanism is disputed |
| Metformin | Large diabetes evidence base. Longevity effect in non-diabetics unproven; TAME trial designed to test it. Attenuates some exercise adaptations |
| Vitamin D3 | Well established where status is low; supplementation in replete adults shows limited additional benefit |
| Vitamin K2 | Reasonable evidence for vascular calcification markers and bone; smaller trials |
| Omega-3 | Substantial cardiovascular evidence base, with trial results that depend heavily on dose and baseline intake |
| Exercise and eating window | Strongest evidence of anything in the list |
The pattern is familiar from other public protocols. The components with the best evidence are the least novel, and the components that built the market, NAD+ precursors and resveratrol, carry the weakest human outcome data.
The Resveratrol Problem
Resveratrol deserves a section of its own because its scientific history is instructive about how a mechanism becomes a product.
The original proposal was that resveratrol activates SIRT1, extending lifespan through the sirtuin pathway. Subsequent work established that the apparent activation was substantially an artefact of the fluorescent substrate used in the assay, and that resveratrol does not activate SIRT1 directly on native substrates. Independent laboratories reported failures to replicate key lifespan findings in model organisms.
The pharmacokinetics compound the problem. Oral resveratrol is absorbed and then almost entirely conjugated, so free plasma concentrations are a small fraction of the doses used in cell culture. Human trials in metabolic and cardiovascular endpoints have been largely unimpressive, and a trial in older adults reported that resveratrol blunted some exercise adaptations.
None of this makes resveratrol harmful at typical doses. It does mean the mechanistic story that sold it is not supported, and that anyone taking it on the strength of the sirtuin account is acting on a superseded model.
The Information Theory of Ageing, and Its Critics
Sinclair's broader framework proposes that ageing is driven primarily by loss of epigenetic information, that this loss is in principle reversible, and that restoring the youthful epigenetic pattern restores youthful function. The supporting work includes optic nerve regeneration in aged mice after partial reprogramming and an induced-ageing model in which epigenetic disruption produced ageing phenotypes.
The scientific disagreement is real and substantive. Critics argue that the evidence for epigenetic change as a primary cause rather than a consequence of ageing is not established, that reprogramming experiments carry teratoma risk and demonstrate feasibility in narrow contexts rather than systemic rejuvenation, and that the framework underweights other hallmarks, particularly somatic mutation and proteostasis, which the theory cannot easily accommodate. Several specific claims in the induced-ageing work have been contested in the literature.
This is a live disagreement among researchers, not a settled matter presented as controversial. A reader is entitled to know that the framework underpinning the most heavily marketed longevity compounds is contested by other people who study ageing for a living. Partial reprogramming remains among the most interesting directions in the field and it is a decade or more from clinical relevance.
What Follows for a Reader
The general lesson matters more than the specific list: a researcher's personal regimen is not evidence, and no researcher's is. It reflects their theoretical commitments, their risk tolerance and their access, and it does not carry the epistemic weight of a trial.
Applied to the components:
If considering an NAD+ precursor, know that NAD+ elevation is reliable and functional benefit in healthy adults is not. It is a reasonable experiment with a defined observation window, not an established intervention.
If considering resveratrol, the mechanistic case has largely dissolved and the bioavailability is poor. The pterostilbene alternative has better bioavailability and thinner outcome data.
Metformin is a prescription medicine. Its use for longevity in people without a metabolic indication is unproven, is being tested, and carries a documented interaction with exercise adaptation that matters for anyone training seriously.
The foundational components, vitamin D where intake or status is low, K2, omega-3, are the parts of the regimen with ordinary evidence behind them and are the least interesting to write about.
The uncomfortable summary is that the best-supported parts of this protocol are the parts that were well supported before it existed.
Reading Any Public Protocol
Three questions handle nearly every published personal regimen.
Which components have human outcome data, and at this dose? Mechanism in a cell line is not the same category of claim.
What would this protocol look like with only the well-evidenced parts? Usually: sleep, training, food quality, energy balance, and correcting a genuine shortfall. That is the residual in almost every case.
Does the person have a commercial interest? Not disqualifying, and material to how the recommendation should be weighted, and it should be disclosed rather than discovered.
Applying these does not require expertise in ageing biology. It requires refusing to let a mechanism substitute for an outcome, which is the single most useful habit a reader of this field can develop.
The AEONNN Perspective
AEONNN's Evidence layer separates mechanism from outcome, and this protocol is the clearest illustration of why that separation is a design requirement rather than a nicety. Resveratrol had a compelling mechanism, a Nobel-adjacent pathway and a market, and the human outcome data did not follow.
The mapping is Pillar 10 and Pillar 1. NAD+ precursors sit in the platform's Evidence Level B: the biochemistry is real, the elevation is measurable, and the functional benefit in healthy adults is unresolved. Resveratrol sits lower on bioavailability grounds, which the Pharmacokinetics layer handles independently of any mechanistic claim.
The Innovation layer tracks the reprogramming work, and the platform does not present a contested framework as consensus. Where researchers who study ageing disagree, a personalisation platform's job is to say so rather than to pick the side that sells more.
Pillar Matrix mapping
Database Matrix layers
- Evidence Layer (PubMed, Cochrane, ClinicalTrials.gov)
- Mechanistic Layer (KEGG, Reactome, UniProt)
- Meta / Consensus Layer (JAMA, BMJ, specialty society positions)
- Innovation Layer (bioRxiv preprints, patent filings)
Frequently Asked
What does David Sinclair take?
Publicly discussed components have included an NAD+ precursor, resveratrol with fat, metformin, vitamin D, vitamin K2 and omega-3, alongside a compressed eating window and regular exercise. The described list has varied across interviews.
Does resveratrol actually activate sirtuins?
The original demonstration was substantially an artefact of the fluorescent assay substrate used. Resveratrol does not activate SIRT1 directly on native substrates, and the mechanistic case has largely dissolved.
Do NAD+ precursors work?
They raise blood NAD+ reliably. Downstream functional benefits in healthy adults are inconsistent across trials, which places them as a reasonable experiment rather than an established intervention.
Should I take metformin for longevity?
It is a prescription medicine, its longevity effect in people without a metabolic indication is unproven and being formally tested, and it attenuates some exercise adaptations. That is a clinical conversation, not a supplement decision.
What is the information theory of aging?
The proposal that ageing is driven primarily by loss of epigenetic information and is in principle reversible. It is a live scientific disagreement, with critics arguing epigenetic change may be a consequence rather than a primary cause.
Is a researcher’s personal protocol evidence?
No. It reflects their theoretical commitments, risk tolerance and access. It does not carry the weight of a trial, and this applies to every published personal regimen.
What parts of the protocol are well supported?
Exercise, the eating pattern, and correcting a genuine nutrient shortfall. These were well supported before the protocol existed and remain its strongest components.
Evidence and review
Any dosage ranges cited here reflect the ranges used in published human trials, not personal recommendations. Evidence in this field moves, so this article is reviewed quarterly and carries its last-updated date above. Nothing here is intended as medical advice, and supplementation should be discussed with a qualified clinician, particularly alongside prescribed medication or an existing condition.